Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/31/2007 First Published: 7/1/1999


1.		Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without SCH 58500 in Patients with Newly Diagnosed Stage III Ovarian Epithelial or Primary Peritoneal Cancer With No Greater Than 2 cm Residual Disease Following Surgery (Summary Last Modified 07/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				SPRI-C/I98-102 SPRI-C98-102, NCI-V99-1544, NCT00003880

Last Modified: 11/1/1998 First Published: 5/1/1998


2.		Phase II Study of SCH 58500 Plus Combination Chemotherapy in Patients with Non-Small Cell Lung Cancer (Summary Last Modified 11/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 74				Pharmaceutical / Industry				SPRI-C/I97-076

Last Modified: 7/1/2000


3.		Phase I Study of Gene Therapy With SCH-58500 (rAd/p53) Via Hepatic Artery Infusion in Patients With Primary and Metastatic Malignant Tumors of the Liver (Summary Last Modified 07/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 to 74				Pharmaceutical / Industry				SPRI-C95-063-01 NCI-V97-1179

Last Modified: 8/1/1997


4.		Phase I Study in Patients with Cutaneous or Subcutaneous, Recurrent Breast Carcinoma or Melanoma Using SCH-58500 (rAd/p53) Administered by Single Intratumoral Dose (Summary Last Modified 08/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 to 75				Pharmaceutical / Industry				SPRI-I/C95-082-01 NCI-V97-1180

Last Modified: 5/1/2000


5.		Phase I Study of SCH-58500 (rAd/p53) Administered by Intraperitoneal Instillation in Patients With Peritoneal Carcinomatosis (Summary Last Modified 05/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				SPRI-I/C95-084 NCI-V97-1181, NCT00002960

Last Modified: 12/1/1998


6.		Phase I Study of SCH-58500 (rAd/p53) Administered by Single Intratumoral Injection for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 to 75				Pharmaceutical / Industry				SPRI-I/C95-177-01 NCI-V97-1182

Last Modified: 12/1/1997


7.		Phase I Study of SCH-58500 (rAd/p53) Administered by Single Intratumoral Injection in Patients With Non-Small Cell Lung Cancer (Summary Last Modified 12/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 to 75				Pharmaceutical / Industry				SPRI-I95-178-02 NCI-V97-1186

Last Modified: 8/1/2001 First Published: 10/1/1999


8.		Phase I Study of SCH-58500 (Adenoviral p53 Gene Therapy) in Patients with Recurrent or Progressive Resectable Glioblastoma Multiforme, Anaplastic Astrocytoma, or Anaplastic Mixed Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NABTT-9703 JHOC-NABTT-9703, NCT00004080

Select All on One Page